ACC Congress 2025 Late-Breaking Science Collection

  • Published:  13 March 2025
  • Likes: 

    Heart Icon

    3

Up Next

ACC Congress 2025 Late-Breaking Science Collection

  • Published:  13 March 2025
  • Likes: 

    Heart Icon

    3

Average (ratings)
No ratings
Your rating
About the episode

ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.

 

Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial investigating the efficacy and safety of lorundrostat in controlling blood pressure for hypertensive patients. Other key outcomes of interest include reductions in systolic and diastolic blood pressure, as well as the tolerability of the drug.

 

Findings showed that lorundrostat effectively lowered 24 hour blood pressure in patients with well treated uncontrolled and resistant hypertension. A dose escalation strategy from 50 to 100mg did not lower blood pressure more than 50mg, and was associated with higher rates of adverse events.

 

Recorded Onsite at ACC 25, Chicago.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Oliver Miles

Support: This is an independent interview produced by Radcliffe CVRM.

Overview

Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the most influential trials.

More from this programme

Faculty Biographies

Luke Laffin

Luke Laffin

Preventive Cardiologist

Dr Luke Laffin is a physician in the Preventive Cardiology & Rehabilitation Section in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart & Vascular Institute. He sees patients at Cleveland Clinic main campus and is the medical director of cardiac rehabilitation. Specialty Interests: Cardiology, preventive cardiology, hypertension (high blood pressure), resistant hypertension, refractory hypertension, cardiovascular risk factor assessment and modification, coronary artery disease, labile blood pressure, ambulatory blood pressure monitoring, home blood pressure monitoring Education: Dr. Laffin earned his medical degree from Vanderbilt University School of Medicine, Nashville, Tenn. He served his residency at University of Chicago Medical Center, Chicago, Ill., followed by fellowships in hypertensive diseases and cardiovascular disease there. He was named to the Cleveland Clinic staff in 2018.

View full profile
Harriette Van Spall

Harriette Van Spall

Associate Professor of Medicine, Director of E-Health and Virtual Care

Dr Harriette Van Spall is an internationally known cardiologist, research methodologist, and senior scientist. She serves as an Associate Professor of Medicine at McMaster University, a Senior Scientist at the Population Health Research Institute, and Director of Implementation Science at the Baim Institute for Clinical Research in Boston.

Academic history

Dr Van Spall completed her BSc and MD at the University of Toronto, followed by residency and fellowship training in internal medicine and…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.